gms | German Medical Science

63. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie (JNS)

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

13. - 16. Juni 2012, Leipzig

Novel candidate for molecular therapeutic targets in gliomas

Meeting Abstract

Suche in Medline nach

  • S. Takahashi - Department of Neurosurgery, Keio University, School of Medicine, Tokyo, Japan
  • M. Toda - Department of Neurosurgery, Keio University, School of Medicine, Tokyo, Japan
  • K. Yoshida - Department of Neurosurgery, Keio University, School of Medicine, Tokyo, Japan

Deutsche Gesellschaft für Neurochirurgie. Japanische Gesellschaft für Neurochirurgie. 63. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie (JNS). Leipzig, 13.-16.06.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. DocFR.07.10

doi: 10.3205/12dgnc223, urn:nbn:de:0183-12dgnc2232

Veröffentlicht: 4. Juni 2012

© 2012 Takahashi et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: In the present study, we screened novel molecular targets for glioma therapy, and verified their validity for clinical use.

Methods: To identify novel therapeutic targets for glioma, we performed two different ways of screening, those are 1: gene expression analysis using cDNA microarray in combination with the result of expression database in internet (NCBI EST database), 2: serological screening (modified SEREX). After screening, we focused on several molecules and performed expression analysis and functional analysis using siRNA technique.

Results: From the result of cDNA microarray, we have identified four candidate genes for glioma-specific genes; (uPARAP, LPAR2, GM2A, CDKN1A). From the result of serological screening we have isolated 6 genes; (SPAG6, LRIG2, Protamine1, KIF23, SYCP1, SMC4). Among the genes screened, we focused on uPARAP and KIF23. Downregulation of uPARAP significantly suppressed glioma cell migration and invasion in vitro. Downregulation of KIF23 expression significantly suppressed glioma cell proliferation in vitro and also in vivo.

Conclusions: Our study identified several candidate molecular target genes for novel glioma therapy. Although downregulation of one gene seems not to be sufficient for glioma treatment, the results could contribute to recognize glioma biology.